Capacitation Medium for Oocyte Maturation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro maturation (IVM) technologies for oocytes from small early antral follicles face challenges in maintaining meiotic arrest and achieving successful nuclear and cytoplasmic maturation, leading to reduced embryonic developmental potential and implantation rates, particularly due to the short duration of oocyte culture and inadequate synchronization of nuclear and cytoplasmic maturation processes.
Innovation Solution
A capacitation medium comprising C-type natriuretic peptide (CNP), estradiol, and Follicle Stimulating Hormone (FSH) is used to maintain meiotic arrest and promote oocyte maturation, allowing for a prolonged culture period that enhances the developmental competence of oocytes from small antral follicles by maintaining cumulus-oocyte connections and delaying meiotic resumption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional IVM culture is used for small early antral follicles, then oocyte collection is simplified, but meiotic arrest cannot be maintained and nuclear-cytoplasmic maturation is not synchronized
Solution Approach 1:
The patent applies preliminary action by pre-treating oocytes with a capacitation medium containing CNP, estradiol, and FSH before formal maturation culture. This preliminary treatment maintains meiotic arrest and prepares the oocytes for subsequent maturation, resolving the contradiction by establishing the necessary conditions before the main maturation process begins.
Solution Approach 2:
The patent changes key chemical parameters by introducing a specific capacitation medium formulation with CNP (0.1-50 nM), estradiol (10-1000 nM), and FSH (0.1-10 mIU/ml) at defined concentrations. These parameter changes enable maintenance of meiotic arrest while allowing subsequent synchronized maturation, transforming the unreliable conventional culture into a controlled process.
2Reliability
If prolonged oocyte culture is implemented to synchronize nuclear and cytoplasmic maturation, then developmental competence improves, but meiotic resumption occurs too early
Solution Approach 1:
The patent uses CNP (C-type natriuretic peptide) as an intermediary substance that mediates between the oocyte and the maturation process. CNP maintains meiotic arrest by activating the cGMP-PKG pathway, which inhibits cAMP degradation. This intermediary allows prolonged culture without premature resumption, enabling synchronized maturation while retaining control over timing.
Solution Approach 2:
The patent implements feedback control through the use of estradiol and FSH in the capacitation medium, which regulate the hormonal environment to maintain meiotic arrest. The medium composition creates a feedback loop that monitors and adjusts the maturation conditions, preventing premature resumption while allowing extended culture for synchronized development.
3Device complexity
If standard capacitation medium is used, then culture protocol is simple, but embryonic developmental potential remains low
Solution Approach 1:
The patent creates a composite capacitation medium by combining multiple substances (CNP, estradiol, FSH, and standard culture components) that work synergistically. This composite formulation provides both the simplicity of a single medium application and the complex biological activity needed for high developmental competence, resolving the contradiction between protocol simplicity and developmental potential.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of the capacitation medium significantly improves the maturation and developmental competence of oocytes, increasing the success rate of embryo development and implantation by extending the meiotic arrest period and promoting chromatin reorganization, thereby overcoming the limitations of existing IVM methods.
Implementation Method 1
NPR2 activity is induced by its ligand natriuretic peptide precursor C (NPPC), which is mainly synthesized by mural granulosa cells and cleaved into the C-type natriuretic peptide (CNP). cGMP is then transferred to the oocyte where it Inhibits the hydrolysis of cAMP by the phosphodiesterase PDE3A.
Implementation Method 2
Intra-oocyte cAMP concentration is regulated by the activity of phosphodiesterase (PDE) enzymes that degrade cAMP. cGMP is then transferred to the oocyte where it Inhibits the hydrolysis of cAMP by the phosphodiesterase PDE3A. This inhibition maintains a high concentration of cAMP and thus blocks meiotic progression.
Implementation Method 3
The cornerstone of the IVM culture is the provision of an appropriate environment for the attainment of developmental competence. This requires mainly hormonal intervention and the activation of necessary signaling pathways by using chemical compounds that allow synchronization of nuclear and cytoplasmic maturation processes within the oocyte.
Data Source
AI summary
The present invention relates to a composition and method for assisted reproductive technology in mammals. In particular, the present invention provides compositions and methods for in vivo maturation of an immature cumulus oocyte complex (COC), thereby enhancing the embryology outcome.